Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vistagen Therapeutics (VTGN) EPS (Basic) (2017 - 2025)

Historic EPS (Basic) for Vistagen Therapeutics (VTGN) over the last 11 years, with Q4 2025 value amounting to -$0.45.

  • Vistagen Therapeutics' EPS (Basic) rose 217.39% to -$0.45 in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.9, marking a year-over-year decrease of 2837.84%. This contributed to the annual value of -$1.67 for FY2025, which is 955.6% down from last year.
  • Per Vistagen Therapeutics' latest filing, its EPS (Basic) stood at -$0.45 for Q4 2025, which was up 217.39% from -$0.54 recorded in Q3 2025.
  • Vistagen Therapeutics' EPS (Basic)'s 5-year high stood at -$0.22 during Q4 2023, with a 5-year trough of -$2.87 in Q2 2022.
  • In the last 5 years, Vistagen Therapeutics' EPS (Basic) had a median value of -$0.6 in 2023 and averaged -$1.07.
  • Per our database at Business Quant, Vistagen Therapeutics' EPS (Basic) tumbled by 398000.0% in 2021 and then soared by 8577.18% in 2024.
  • Vistagen Therapeutics' EPS (Basic) (Quarter) stood at -$1.59 in 2021, then increased by 10.69% to -$1.42 in 2022, then skyrocketed by 84.51% to -$0.22 in 2023, then crashed by 109.09% to -$0.46 in 2024, then increased by 2.17% to -$0.45 in 2025.
  • Its EPS (Basic) was -$0.45 in Q4 2025, compared to -$0.54 in Q3 2025 and -$0.47 in Q2 2025.